Michael Liptay to Disease-Free Survival
This is a "connection" page, showing publications Michael Liptay has written about Disease-Free Survival.
Connection Strength
0.226
-
Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
Score: 0.083
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.036
-
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
Score: 0.033
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
Score: 0.031
-
Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
Score: 0.022
-
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
Score: 0.021